Anders Tuv

Nextera AS provides drug research for therapeutic interventions for autoimmune diseases, chronic infections, and cancer. It offers platform for protein engineering and evolution, such as life sciences, drug discovery, and lead optimization fields. The firm’s core competence lies within protein engineering and evolution utilizing its technology to epitope discovery and epitope validation, as well as lead-candidate generation and validation in-vitro. The company was founded by Geir Åge Løset and Inger Sandlie in 2009 and is headquartered in Oslo, Norway.

Radiumhospitalets Forskningsstiftelse invests in companies from Nordic research institutions. It is a pre-seed investor and project developer focused on cancer. It strengthens cancer research at Rikshospitalet University Hospital, including The Norwegian Radium Hospital. It provides Oslo Cancer Cluster with the necessary infrastructure and management team, as well. The company was founded in 1986 and is headquartered in Lysaker, Norway.

Zelluna Immunotherapy AS engages in research and development on biotechnology. The company is headquartered in Oslo, Norway.

Part of Artbio, Inc., Artbio AS is a clinical-stage radiopharmaceutical biotechnology business that works to create a new class of alpha radio ligand medicines. The company is based in Oslo, Norway. The Norwegian company was founded in 2018. The CEO is Emanuele Ostuni.

OncoImmunity AS develops software solutions that facilitate patient selection for cancer immunotherapy. It offers proprietary machine-learning based software to address the key knowledge gaps in the prediction of bone fide immunogenic neoantigens for personalized cancer immunotherapy. The company was founded by Richard Stratford and Trevor Clancy in 2014 and is headquartered in Oslo, Norway.

Oslo Cancer Cluster NCE is an oncology research firm that specializes in developing cancer diagnostics and medicines. The private company is based in Oslo, Norway.